Skip to main content
Top
Literature
1.
2.
go back to reference Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844 Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844
3.
go back to reference Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176PubMedCrossRef Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176PubMedCrossRef
4.
go back to reference Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698PubMedPubMedCentralCrossRef Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698PubMedPubMedCentralCrossRef
5.
go back to reference Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223PubMedPubMedCentralCrossRef Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223PubMedPubMedCentralCrossRef
6.
go back to reference Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707 Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707
Metadata
Title
Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema
Authors
Sumeet P. Mirgh
Rayaz Ahmed
Narendra Agrawal
Sneha Bothra
Bhaarat Mohan
Ambar Garg
Shinto Francis Thekkudan
Vishvdeep Khushoo
Dinesh Bhurani
Publication date
01-01-2020
Publisher
Springer India
Keywords
Edema
Ibrutinib
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01181-y

Other articles of this Issue 1/2020

Indian Journal of Hematology and Blood Transfusion 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine